Ezetimibe: Rationale and role in the management of hypercholesterolemia

Clinical Cardiology

Volumn 29, Issue 2, 2006, Pages 52-55

  Yatskar, Leonid ^a   Fisher, Edward A ^a,b   Schwartzbard, Arthur ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol absorption; Ezetimibe; Hypercholesterolemia; Lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL TRANSPORTER INHIBITOR; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN INHIBITOR; STANOL ESTER; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW;

EID: 32544442885     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290203     Document Type: Review

References (32)

1. Assmann G, Cullen P, Schulte H: The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(suppl A):A2-11
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239
3. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-467
4. Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987; 17:391-395
5. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204
6. Turley SD, Dietschy JM: The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prevent Cardiol 2003;6(1):29-33
7. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, Angelin B: Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(suppl 1):S53-S58
8. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-364
9. Nguyen TT: The cholesterol-lowering action of plant stanol esters. J Nutr 1999;129(12):2109-2112
10. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333(20):1308-1312
11. Plat J, Kerckhoff DA, Mensink RP: Therapeutic potential of plant sterols and stanols. Curr Opin Lipidol 2000;11(6):571-576
12. Lichtenstein AH, Deckelbaum RJ: AHA Science Advisory: Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for health-care professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001;103(8):1177-1179
13. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106(15):1943-1948
14. van Heek M, Farley C, Compton DS, Hoos L, Davis HR: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134(2):409-417
15. Knopp RH, Bays HE, Manion CV: Effect of ezetimibe on serum concentrations of lipid-soluble vitamins (abstr). Atherosclerosis 2001;2(suppl):90
16. Zetia (Ezetimibe): Prescribing information. Package insert. Merck/Schering-Plough Pharmaceuticals, 2001
17. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK: A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001;23(6):871-885
18. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP: Esetimibe Study Group: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1092-1097
19. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP: Ezetimibe Study Group: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001;23(8):1209-1230
20. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B: Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1084-1091
21. Gagne C, Gaudet D, Bruckert E, The Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105(21);2469-2475
22. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40(12): 2125-2134
23. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93: 1487-1494
24. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: The American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute: ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106(8):1024-1228
25. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107(3):363-369
26. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168
27. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107(13):1783-1790
28. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344 (26):1959-1965
29. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-2415
30. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
31. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators: Intensive lipid-lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
32. Pedersen TR, Faergemann O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, for the Incremental Decrease in End Point Through Aggressie Lipid Lowering (IDEAL) Study Group: High-dose atovastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial. J Am Med Assoc 2005;294:2437-2445